Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experience.
Picard C, Hayette S, Bilhou-Nabera C, Cayuela JM, Delabesse E, Frenoy N, Preudhomme C, Dupont M, Bastard C, Bories D, Vaerman JL, Davi F, Dastugue N, Raynaud S, Lafage M, Deschaseaux F, Fest T, Gaub MP, Lhéritier V, Thomas X, Charrin C, Boucheix C, Dombret H, Macintyre E, Fière D, Gabert J. Picard C, et al. Among authors: bories d. Leukemia. 2006 Dec;20(12):2178-81. doi: 10.1038/sj.leu.2404408. Epub 2006 Oct 12. Leukemia. 2006. PMID: 17039237 No abstract available.
Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study.
Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela JM, Dombret H, Dastugue N, Huguet F, Bastard C, Stamatoulas A, Giollant M, Tournilhac O, Macintyre E, Buzyn A, Bories D, Kuentz M, Dreyfus F, Delannoy A, Raynaud S, Gratecos N, Bordessoule D, de Botton S, Preudhomme C, Reman O, Troussard X, Pigneux A, Bilhou C, Vernant JP, Boucheix C, Gabert J; GET-LALA Group the Swiss Group for Clinical Cancer Research (SAKK). Vey N, et al. Among authors: bories d. Leukemia. 2006 Dec;20(12):2155-61. doi: 10.1038/sj.leu.2404420. Epub 2006 Oct 12. Leukemia. 2006. PMID: 17039234 Clinical Trial.
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
Nicolini FE, Corm S, Lê QH, Sorel N, Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, Facon T, Mahon FX, Cayuela JM, Rousselot P, Michallet M, Preudhomme C, Guilhot F, Roche-Lestienne C. Nicolini FE, et al. Among authors: bories d. Leukemia. 2006 Jun;20(6):1061-6. doi: 10.1038/sj.leu.2404236. Leukemia. 2006. PMID: 16642048
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M, Guilhot F, Legros L, Maloisel F, Kiladjian JJ, Mahon FX, Lê QH, Michallet M, Roche-Lestienne C, Preudhomme C. Nicolini FE, et al. Among authors: bories d. Haematologica. 2007 Sep;92(9):1238-41. doi: 10.3324/haematol.11369. Haematologica. 2007. PMID: 17768119 Free article.
Infusion of allogeneic-related HLA mismatched mesenchymal stem cells for the treatment of incomplete engraftment following autologous haematopoietic stem cell transplantation.
Fouillard L, Chapel A, Bories D, Bouchet S, Costa JM, Rouard H, Hervé P, Gourmelon P, Thierry D, Lopez M, Gorin NC. Fouillard L, et al. Among authors: bories d. Leukemia. 2007 Mar;21(3):568-70. doi: 10.1038/sj.leu.2404550. Epub 2007 Jan 25. Leukemia. 2007. PMID: 17252011 No abstract available.
Complete remission with bortezomib on plasmocytomas in an end-stage patient with refractory multiple myeloma who failed all other therapies including hematopoietic stem cell transplantation: possible enhancement of graft-vs-tumor effect.
Paubelle E, Coppo P, Garderet L, Azizi L, Bories D, Gorin NC, Fouillard L. Paubelle E, et al. Among authors: bories d. Leukemia. 2005 Sep;19(9):1702-4. doi: 10.1038/sj.leu.2403855. Leukemia. 2005. PMID: 16001088 No abstract available.
CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cheraï M, Beaumont JL, Azar N, Dhedin N, Sirvent A, Buzyn A, Rubio MT, Vigouroux S, Montagne O, Bories D, Roudot-Thoraval F, Vernant JP, Cordonnier C, Klatzmann D, Cohen JL. Maury S, et al. Among authors: bories d. Sci Transl Med. 2010 Jul 21;2(41):41ra52. doi: 10.1126/scitranslmed.3001302. Sci Transl Med. 2010. PMID: 20650872 Clinical Trial.
Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.
Algrin C, Golmard JL, Michallet M, Reman O, Huynh A, Perrot A, Sirvent A, Plesa A, Salaun V, Béné MC, Bories D, Tournilhac O, Merle-Béral H, Leblond V, Le Garff-Tavernier M, Dhedin N. Algrin C, et al. Among authors: bories d. Eur J Haematol. 2017 Apr;98(4):363-370. doi: 10.1111/ejh.12836. Epub 2017 Jan 30. Eur J Haematol. 2017. PMID: 27943415 Clinical Trial.
48 results